نتایج جستجو برای: overall response rate orr

تعداد نتایج: 2165667  

Journal: :Blood 2016
John C Byrd Joseph M Flynn Thomas J Kipps Michael Boxer Kathryn S Kolibaba David J Carlile Guenter Fingerle-Rowson Nicola Tyson Jamie Hirata Jeff P Sharman

Obinutuzumab is a glycoengineered, type 2 anti-CD20 humanized antibody with single-agent activity in relapsed chronic lymphocytic leukemia (CLL). With other CD20 antibodies, a dose-response relationship has been shown. We therefore performed a randomized phase 2 study in symptomatic, untreated CLL patients to evaluate if an obinutuzumab dose response exists. Obinutuzumab was given at a dose of ...

2016
Yinghui Liu Zuen Ren Jinghui Wang Shucai Zhang

BACKGROUND The correlation between epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and EGFR sensitive mutation subtypes in advanced or metastatic non-small cell lung cancer (NSCLC) remains uncertain. We performed this meta-analysis to determine different clinical outcomes between patients with exon 19 deletion accepting EGFR-TKI therapy compared with those with exon 21 L...

2017
Qing Li Tao Wu Li Jing Miao-Jing Li Tao Tian Zhi-Ping Ruan Xuan Liang Ke-Jun Nan Zhi-Yan Liu Yu Yao Hui Guo

BACKGROUND This study aimed to assess the effectiveness and safety of angiogenesis inhibitors for the treatment of patients with small cell lung cancer (SCLC) via meta-analysis. METHODS Electronic databases including PubMed, Embase, and Cochrane Library were searched to look for eligible studies through February 1, 2016. RCTs comprising angiogenesis inhibitors and nonangiogenesis inhibitors f...

Journal: :Oncotarget 2015
Seong Hyun Jeong Yoo-Jin Kim Je-Hwan Lee Yeo-Kyeoung Kim Soo Jeong Kim Sung Kyu Park Young Rok Do Inho Kim Yeung-Chul Mun Hoon Gu Kim Won Sik Lee Hyeon Gyu Yi Young-Don Joo Chul Won Choi Suk Ran Kim Sang Min Na Jun Ho Jang

This prospective observational study evaluated the efficacy and safety of long-term decitabine treatment in patients with myelodysplastic syndrome (MDS). Decitabine 20 mg/m(2)/day was administered intravenously for 5 consecutive days every 4 weeks to MDS patients in intermediate-1 or higher International Prognostic Scoring System (IPSS) risk categories. Active antimicrobial prophylaxis was give...

Journal: :American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006
R L Elstrom C Andreadis N A Aqui V N Ahya R D Bloom S C Brozena K M Olthoff S J Schuster S D Nasta E A Stadtmauer D E Tsai

Information regarding treatment of post-transplant lymphoproliferative disease (PTLD) beyond reduction in immunosuppression (RI) is limited. We retrospectively evaluated patients receiving rituximab and/or chemotherapy for PTLD for response, time to treatment failure (TTF) and overall survival (OS). Thirty-five patients met inclusion criteria. Twenty-two underwent rituximab treatment, with over...

2016
Dan-Zeng Ba-Sang Zi-Wen Long Hao Teng Xu-Peng Zhao Jian Qiu Ming-Shan Li

OBJECTIVE A network meta-analysis was conducted comparing the short-term efficacies of 16 targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer (CRC). RESULTS Twenty-seven RCTs were ultimately incorporated into this network meta-analysis. Compared with chemotherapy alone, bevacizumab + chemotherapy, panitumumab + chemotherapy and conatumumab + ...

Journal: :Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2014
Li Zou Jun Qian

OBJECTIVE To evaluate the predictive value of decline in the serum level of carbohydrate antigen 724 (CA724) on tumor response during the chemotherapy in patients with advanced gastric carcinoma (GC). METHODS The serum CA724 level was determined by electrochemiluminescence immunoassay, while the objective response rate (ORR) was assessed according to response evaluation criteria in solid tumo...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
H von der Maase J Lehmann G Gravis H Joensuu P F Geertsen J Gough G Chen M Kania

BACKGROUND Both pemetrexed and gemcitabine have single-agent activity in bladder cancer, but the combination of these two drugs has not been previously evaluated for safety and efficacy in this disease. Thus, the objectives in the current study were to determine overall response rate (ORR), progression-free survival, overall survival and safety and toxicity in chemonaive patients with locally a...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2015
R Angelo de Claro Karen M McGinn Nicole Verdun Shwu-Luan Lee Haw-Jyh Chiu Haleh Saber Margaret E Brower C J George Chang Elimika Pfuma Bahru Habtemariam Julie Bullock Yun Wang Lei Nie Xiao-Hong Chen Donghao Robert Lu Ali Al-Hakim Robert C Kane Edvardas Kaminskas Robert Justice Ann T Farrell Richard Pazdur

On November 13, 2013, the FDA granted accelerated approval to ibrutinib (IMBRUVICA capsules; Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. On February 12, 2014, the FDA granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. ...

2016
Lawrence Chen Chiehfeng Chen Yun Yen Ka-Wai Tam

BACKGROUND Although gemcitabine and platinum-based agents (GP) are currently regarded as the standard chemotherapy for advanced biliary tract cancer (BTC), the prognosis remains poor. Combinations with fluoropyrimidines and targeted therapy have demonstrated modest benefits. Therefore, we conducted a meta-analysis of randomized controlled trials to evaluate the efficacy of different chemotherap...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید